Thus, selective CTLA4 deficiency may revitalize functionally impaired T cells in patients with chronic lymphocytic leukemia (CLL), providing a strategy to enhance patient responsiveness to CAR-T-cell therapy [80]. This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.